

1 / 21




FIG. 1A

2 / 21




FIG. 1B




FIG. 1C




FIG. 1D

3 / 21




FIG. 2A

4 / 21




FIG. 2B

5 / 21




FIG. 3 -

6 / 21




FIG. 4A




FIG. 4B

7 / 21




FIG. 5

8 / 21




FIG. 6A




FIG. 6B




FIG. 6C

9 / 21




FIG. 6D




FIG. 6E




FIG. 6F

10 / 21




FIG. 7




FIG. 8


12 / 21

K5-Cre-ER^{T3}

K5-Cre-ER^{T2}

K5-Cre-ER^{T3}

K5-Cre-ER^{T2}



OHT (0.1mg)

OHT (1mg)

FIG. 9

13 / 21




FIG. 10

14 / 21




FIG. 11

15 / 21




A**B**

FIG. 12A-B

16/21


C



CT

RXR α ep-/-

D



CT

RXR α ep-/-

FIG. 12C-D

17 / 21




FIG. 13A-B

18 / 21

Histological analysis of paraffin sections (5 μ m-thick) of biopsies of 8-16 mm tumors from CT and RXR α ep-/- mice, 25 and 30 weeks after the start of the DMBA/TPA treatment

Mouse	Weeks After DMBA/TPA	Number of papillomas	Papillomas exhibiting							
			In situ carcinoma	FC	SCC (I)	SCC (II)	SCC (III)	SCC (IV)	SpCC	BCC
CT	25	20	1/20 (5%)	0/20	0/20	0/20	0/20	0/20	0/20	0/20
	30	31	1/31 (~3%)	5/31 (~16%)	0/31	0/31	0/31	0/31	0/31	0/31
RXR α ep-/-	25	20	2/20 (10%)	8/20 (40%)	0/20	0/20	0/20	0/20	0/20	0/20
	30	35	1/35 (~3%)	7/35 (20%)	3/35 (~9%)	3/35 (~9%)	1/35 (~3%)	2/35 (~6%)	2/35 (~6%)	3/35 (~9%)

FC, focal carcinoma; SCC, squamous cell carcinoma; SpCC, spindle cell carcinoma; BCC, basal cell carcinoma

FIG. 13C

20 / 21




FIG. 14C

21 / 21




FIG. 15